DarioHealth ( (DRIO) ) has released its Q3 earnings. Here is a breakdown of the information DarioHealth presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
DarioHealth Corp. is a global digital therapeutics company specializing in personalized, evidence-based interventions driven by precision data analytics, software, and personalized coaching, primarily focusing on chronic condition management. In its latest earnings report for the quarter ending September 30, 2025, DarioHealth reported a decrease in total revenues to $5.007 million from $7.423 million in the same period last year. The company continues to face challenges with a net loss of $10.466 million for the quarter, compared to a net loss of $12.330 million in the previous year. Key financial metrics indicate a reduction in operating expenses, which decreased to $12.499 million from $15.907 million year-over-year, reflecting the company’s efforts to streamline operations. Despite the ongoing financial challenges, DarioHealth’s management remains focused on expanding its digital therapeutic solutions and improving its financial health. Looking forward, the company aims to leverage its innovative platform to enhance market penetration and achieve sustainable growth.